Format

Send to

Choose Destination
Br J Haematol. 2015 Nov;171(3):344-54. doi: 10.1111/bjh.13582. Epub 2015 Jul 7.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

Author information

1
c/o First Department of Medicine, Centre for Oncology, Haematology and Palliative Care, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
2
Landeskrankenhaus, Universitätsklinik für Innere Medizin III, Salzburg, Austria.
3
Department of Haematology and Stem Cell Transplantation, St István and St László Hospital, Budapest, Hungary.
4
First Faculty of Medicine, First Medical Department, Clinical Department of Haematology, Charles University in Prague, Prague, Czech Republic.
5
Institute of Haematology, Assuta Medical Centre, Tel-Aviv, Israel.
6
Department of Haemato-oncology, FN Ostrava and Faculty of Medicine, Ostrava, Czech Republic.
7
Medical University of Lublin, Lublin, Poland.
8
Centro de Investigación Médica Aplicada (CIMA), Clínica Universidad de Navarra, Pamplona, Spain.
9
IBMCC (USAL-CSIC), Hospital Universitario Salamanca, CIC, Salamanca, Spain.
10
Hospital de Dia de Hematologia, Hospital de Santa Maria, Lisbon, Portugal.
11
Institut Paoli-Calmettes, Marseille, France.
12
Janssen Global Services, LLC, Raritan, NJ, USA.
13
Janssen Research & Development, LLC, Spring House, PA, USA.
14
Division of Janssen-Cilag Limited, Janssen Research & Development, High Wycombe, UK.
15
Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium.
16
Serviço de Onco-Hematologia, Instituto Português de Oncologia do Porto Francisco Gentil, Entidade Pública Empresarial (IPOPFG, EPE), Porto, Portugal.

Abstract

This follow-up extension of a randomised phase II study assessed differences in long-term outcomes between bortezomib-thalidomide-dexamethasone (VTD) and VTD-cyclophosphamide (VTDC) induction therapy in multiple myeloma. Newly diagnosed patients (n = 98) were randomised 1:1 to intravenous bortezomib (1·3 mg/m(2); days 1, 4, 8, 11), thalidomide (100 mg; days 1-21), and dexamethasone (40 mg; days 1-4, 9-12), with/without cyclophosphamide (400 mg/m(2); days 1, 8), for four 21-day cycles before stem-cell mobilisation/transplantation. After a median follow-up of 64·8 months, median time-to-next therapy was 51·8 and 47·9 months with VTD and VTDC, respectively. Type of subsequent therapy was similar in both arms. After adjusting for asymmetric censoring, median time to progression was not significantly different between VTD and VTDC [35·7 vs. 34·5 months; Hazard ratio (HR) 1·26, 95% confidence interval: 0·76-2·09; P = 0·370]. Five-year survival was 69·1% and 65·3% with VTD and VTDC, respectively. When analysed by minimal residual disease (MRD) status, overall survival was longer in MRD-negative versus MRD-positive patients with bone marrow-confirmed complete response (HR 3·66, P = 0·0318). VTD induction followed by transplantation provides long-term disease control and, consistent with the primary analysis, there is no additional benefit from adding cyclophosphamide. This study was registered at ClinicalTrials.gov (NCT00531453).

KEYWORDS:

minimal residual disease; multiple myeloma; transplantation

PMID:
26153365
PMCID:
PMC4758383
DOI:
10.1111/bjh.13582
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center